Note: This document contains side effect information about pegaspargase. Some of the dosage forms listed on this page may not apply to the brand name Oncaspar.
Applies to pegaspargase: parenteral injection
Side effects include:
Hypersensitivity reactions, coagulopathy, hyperglycemia, elevated serum transaminase concentrations, hyperbilirubinemia, pancreatitis, CNS thrombosis. No apparent difference in adverse effects following IV versus IM administration.
Applies to pegaspargase: injectable solution
The most commonly reported side effects were elevated transaminases and clinical allergic reactions to asparaginase (including bronchospasm, hypotension, laryngeal edema, local erythema or swelling, systemic rash, and urticaria).
Very common (10% or more): Hypersensitivity, urticaria, anaphylactic reaction
Common (1% to 10%): Central nervous system thrombosis/hemorrhage, seizure, peripheral motor neuropathy, syncope
Rare (less than 0.1%): Posterior reversible leukoencephalopathy syndrome
Frequency not reported: Somnolence, tremor
Common (1% to 10%): Thrombosis, embolism
Very common (10% or more): Pancreatitis, diarrhea, abdominal pain, nausea
Common (1% to 10%): Vomiting, stomatitis, ascites
Rare (less than 0.1%): Pancreatitis necrotizing, pancreatitis hemorrhagic
Frequency not reported: Pancreatic pseudocyst, parotitis
Very common (10% or more): Febrile neutropenia
Common (1% to 10%): Coagulopathy (prolonged prothrombin time or partial thromboplastin time; or hypofibrinogenemia), anemia
Frequency not reported: Bone marrow failure
Very common (10% or more): Elevated transaminases
Common (1% to 10%): Hyperbilirubinemia, hepatotoxicity, fatty liver
Rare (0.01% to 0.1%): Hepatic necrosis, jaundice, cholestasis, hepatic failure
Common (1% to 10%): Hyperglycemia, weight decreased, decreased appetite
Frequency not reported: Glucose intolerance, hyperlipidemia, hypercholesterolemia, diabetic ketoacidosis, hypoglycemia
Common (1% to 10%): Infections, sepsis
Common (1% to 10%): Pain in extremities
Frequency not reported: Confusion
Common (1% to 10%): Hypoxia
Frequency not reported: Pyrexia
Frequency not reported: Acute renal failure
Very common (10% or more): Rash
Frequency not reported: Toxic epidermal necrolysis (TEN), cerebrovascular accident, hemorrhage, superior sagittal sinus thrombosis
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Oncaspar